Based on the profile of genetic alterations occurring in tumor samples from selected diffuse
large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies …

To identify, in high-resolution regions of DNA, the copy number changes associated with
outcome in patients with diffuse large B-cell lymphoma (DLBCL), a disease with an …

The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell
lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated …

Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is
increasingly impelling in diffuse large B-cell lymphoma (DLBCL). Cell-free DNA (cfDNA) is …

Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …

Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …

Abstract The 2016 World Health Organization classification defines diffuse large B-cell
lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and oncogenic …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of
at least 2 molecular subtypes that differ in gene expression and distribution of mutations …

Expression profiling has shown 2 main and clinically distinct subtypes of diffuse large B-cell
lymphomas (DLBCLs): germinal-center B cell–like (GCB) and activated B cell–like (ABC) …